http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109833321-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_008c9107ff464e201e724ad32b7630cc |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-196 |
| filingDate | 2017-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3059e696380c352fc124336aa628bcc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd7adc3961b66f442010346a2bcb3f77 |
| publicationDate | 2019-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109833321-A |
| titleOfInvention | It is a kind of to reverse liver cancer cells to the pharmaceutical composition of sorafenib drug resistance |
| abstract | Pharmaceutical composition of the invention is related to inhibitor Aspirin, Flufenamic acid of the key enzyme AKR1C3 on a kind of prostaglandin synthesis access, and collaboration Sorafenib can reverse liver cancer cells to the drug resistance of sorafenib in low concentration.The method specifically used is the sorafenib collective effect of AKR1C3 inhibitor Aspirin, Flufenamic acid and low concentration in the drug resistant HepG2 hepatoma cell strain of sorafenib, the growth of the drug resistant HepG2 cell of sorafenib can significantly be inhibited, thus to overcome sorafenib drug resistance to provide effective method. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021110085-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114917214-A |
| priorityDate | 2017-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.